Imovax Rabies Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high rabies fatality rates, widespread animal bite exposure, early vaccine development success, public immunization campaigns, hospital administered vaccination protocols.

The growth in the forecast period can be attributed to increasing travel to rabies endemic regions, expansion of veterinary public health programs, improved vaccine access in developing regions, rising awareness of preventive care, stronger government vaccination mandates. Major trends in the forecast period include rising demand for rabies vaccination, expansion of pre exposure immunization programs, growth in post exposure prophylaxis use, increasing focus on preventive vaccination, strengthening global rabies control initiatives.

The rise in rabies cases is expected to drive the growth of the Imovax Rabies market going forward. Rabies cases refer to infections caused by the rabies virus, typically transmitted through animal bites, leading to severe neurological symptoms and often death if left untreated. The increase in rabies cases is generally attributed to greater contact between humans and infected animals, inadequate vaccination of pets, and limited access to timely medical treatment in certain regions. Imovax Rabies prevents the onset of rabies after exposure by stimulating the immune system to produce antibodies against the virus. For example, in April 2024, the South Dakota Department of Health, a US-based government agency, reported that in 2023, around 20 animals in South Dakota were confirmed to have rabies, representing a 122% increase from the 9 cases reported in 2022. Therefore, the rise in rabies cases is driving the growth of the Imovax Rabies market.

The increasing number of animal-related activities is expected to drive the growth of the Imovax Rabies market moving forward. Animal-related activities refer to procedures involving animals for research, experimentation, breeding, and genetic alteration purposes. The rise in these activities can be attributed to factors such as growing interest in outdoor recreation, urban expansion into wildlife areas, and increasing pet ownership and animal companionship. Imovax Rabies is primarily used in animal-related activities for research and vaccine development to prevent and control rabies in both humans and animals. For example, in August 2025, the U.S. Bureau of Labor Statistics, a US-based intergovernmental organization, projected that an average of about 81,700 job openings for animal care and service workers would occur annually over the next decade, with employment in this field expected to grow by 11% from 2024 to 2034. As a result, the rise in animal-related activities is contributing to the growth of the Imovax Rabies market.

The growing pet adoption is also expected to contribute to the expansion of the Imovax Rabies market. The rise in pet ownership is driven by increasing awareness of pet care, changing lifestyles, and the growing human-animal bond. Imovax Rabies is used in pets for post-exposure prophylaxis or pre-exposure vaccination to protect against rabies infection. For instance, in July 2025, the World Animal Foundation (WAF), a US-based non-profit animal welfare organization, reported that dog adoption rates showed a modest year-on-year increase, rising from 56% in 2023 to 57% in 2024, while cat adoption rates continued to be a strong growth driver, increasing from 62% in 2023 to 64% in 2024. As a result, the growing adoption of pets is further fueling the growth of the Imovax Rabies market.

Major companies operating in the imovax rabies market are Sanofi SA.

North America was the largest region in the imovax rabies market in 2025. The regions covered in the imovax rabies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the imovax rabies market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the imovax rabies market by increasing costs related to vaccine production inputs, sterile packaging, and international logistics. These effects are most pronounced in hospital and public health distribution channels across regions reliant on imported rabies vaccines. Higher tariffs may limit vaccine affordability and coverage in low income settings. At the same time, tariffs are promoting local vaccine manufacturing, technology transfer, and regional supply chain resilience to support long term rabies prevention efforts.

The imovax rabies market research report is one of a series of new reports that provides imovax rabies market statistics, including imovax rabies industry global market size, regional shares, competitors with a imovax rabies market share, detailed imovax rabies market segments, market trends and opportunities, and any further data you may need to thrive in the imovax rabies industry. This imovax rabies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Imovax Rabies is an inactivated rabies vaccine used to prevent rabies infection in humans. It is typically administered as a series of intramuscular injections, either for pre-exposure prophylaxis for individuals at high risk or post-exposure prophylaxis following potential rabies exposure, such as a bite from a rabid or potentially rabid animal.

The primary patient demographics for Imovax Rabies include pediatric patients, adult patients, and high-risk groups. Pediatric patients refer to children who are at risk of rabies exposure, either due to bites from infected animals or travel to areas where rabies is endemic. Children may require specific dosages and treatments for rabies prevention, and Imovax Rabies addresses these needs with vaccines tailored for young patients. It is distributed through various channels such as hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is used for applications like post-exposure prophylaxis and pre-exposure prophylaxis.

The imovax rabies market consists of sales of rabies vaccine inactivated (DCO). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.